BioArctic

BioArctic PP&E per Employee

The PP&E per Employee of BioArctic (BIOA B.ST) as of Oct 15, 2026 is 1.93 M SEK. In the previous year, PP&E per Employee was 2.25 M SEK — a change of -14.11% (lower).

PP&E per Employee

1.93 MSEK

YoY

-14.11%

Last updated:

PP&E per Employee of BioArctic is 2025 1.93 M SEK. PP&E per Employee of BioArctic was 2024 2.25 M SEK. It decreases by -14.11% lower compared to the previous year.

The BioArctic PP&E per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PP&E per Employee
Date
PP&E per Employee
Jan 1, 2018
216,023.26 SEK
Jan 1, 2019
863,581.40 SEK
Jan 1, 2020
928,837.21 SEK
Jan 1, 2021
784,837.21 SEK
Jan 1, 2022
820,093.02 SEK
Jan 1, 2023
723,860.47 SEK
Jan 1, 2024
2.25 M SEK
Jan 1, 2025
1.93 M SEK
The BioArctic PP&E per Employee history
YEARPP&E per EmployeeYoY
1.93 MSEK-14.11%
2.25 MSEK+210.42%
723,860.47SEK-11.73%
820,093.02SEK+4.49%
784,837.21SEK-15.50%
928,837.21SEK+7.56%
863,581.40SEK+299.76%
216,023.26SEK+30.96%
164,953.49SEK+25.67%
131,255.81SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

PP&E per Employee of BioArctic is 1.93 M SEK in 2025.

PP&E per Employee of BioArctic changed from 2.25 M SEK to 1.93 M SEK, representing a -14.11% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of PP&E per Employee BioArctic since 2006 – with annual values, charts, and detailed analysis.

PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.

PP&E per Employee's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's BioArctic historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — BioArctic

All Key Metrics — BioArctic